Reyvow and Visual impairment - a phase IV clinical study of FDA data

Summary:

Visual impairment is reported as a side effect among people who take Reyvow (lasmiditan succinate), especially for people who are female, 20-29 old, have been taking the drug for < 1 month also take Xanax, and have Migraine.

The phase IV clinical study analyzes which people have Visual impairment when taking Reyvow. It is created by eHealthMe based on reports of 1,004 people who have side effects when taking Reyvow from the FDA, and is updated regularly.

What is Reyvow?

Reyvow has active ingredients of lasmiditan succinate. eHealthMe is studying from 1,006 Reyvow users. Check the latest studies of Reyvow.

What is Visual impairment?

Visual impairment is found to be associated with 2,248 drugs and 2,336 conditions by eHealthMe. Check the latest studies of Visual impairment.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

1,004 people reported to have side effects when taking Reyvow.
Among them, 12 people (1.2%) have Visual impairment.

Among these 12 people:

How long have people been on Reyvow when they have Visual impairment? *

What is the gender of people who have Visual impairment when taking Reyvow? *

female: 83.33 %
male: 16.67 %

What is the age of people who have Visual impairment when taking Reyvow? *

What are other drugs people take besides Reyvow? *

What are other side effects people have besides Visual impairment? *

Migraine (headache): 5 people, 41.67%
Fatigue (feeling of tiredness): 4 people, 33.33%
Derealisation: 4 people, 33.33%
Dizziness: 4 people, 33.33%
Polycystic Ovary Disease (cysts in the ovaries that occurs when the follicle stops developing): 3 people, 25.00%
Adrenal Mass: 3 people, 25.00%
Stress And Anxiety: 3 people, 25.00%
Nausea (feeling of having an urge to vomit): 3 people, 25.00%
Weight Decreased: 2 people, 16.67%
Hallucination, Visual (seeing things that aren't there): 2 people, 16.67%

What are the existing conditions these people have? *

Migraine (headache): 9 people, 75.00%
Stress And Anxiety: 3 people, 25.00%
Nausea (feeling of having an urge to vomit): 3 people, 25.00%
Insomnia (sleeplessness): 3 people, 25.00%
Blood Testosterone Increased: 2 people, 16.67%
Bipolar Ii Disorder (characterized by at least one episode of hypomania and at least one episode of major depression): 2 people, 16.67%
Appetite Disorder (abnormal eating habits): 2 people, 16.67%
Adrenal Insufficiency (a condition in which the adrenal glands do not produce adequate amounts of steroids): 2 people, 16.67%

* Approximation only. Some reports may have incomplete information.

Do you take Reyvow and have Visual impairment?

- Check whether Visual impairment is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Reyvow:

Reyvow (1,006 reports)

Visual impairment treatments and more:

Visual impairment (128,338 reports)

Browse all side effects of Reyvow:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Visual impairment:

Visual impairment (2,248 drugs)

Browse all the conditions that are associated with Visual impairment:

Visual impairment (2,336 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lasmiditan succinate (the active ingredients of Reyvow) and Reyvow (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.